Structure Therapeutics (NASDAQ:GPCR) Issues Earnings Results, Misses Expectations By $0.33 EPS

Structure Therapeutics (NASDAQ:GPCR) released its quarterly earnings results on Monday. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.33), FiscalAI reports.

Structure Therapeutics Price Performance

Shares of NASDAQ:GPCR traded up $1.06 during midday trading on Monday, reaching $21.41. The company had a trading volume of 1,235,652 shares, compared to its average volume of 966,528. The stock has a market capitalization of $1.49 billion, a P/E ratio of -21.41 and a beta of -1.12. The stock’s fifty day moving average price is $30.52 and its 200-day moving average price is $47.81. Structure Therapeutics has a one year low of $18.70 and a one year high of $94.90.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on GPCR shares. Weiss Ratings raised shares of Structure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday. HC Wainwright reaffirmed a “buy” rating on shares of Structure Therapeutics in a research report on Wednesday, September 9th. Wall Street Zen cut Structure Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 3rd. Canaccord Genuity Group set a $111.00 price target on Structure Therapeutics in a research note on Friday, August 7th. Finally, Citigroup reissued a “market outperform” rating on shares of Structure Therapeutics in a report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Structure Therapeutics has an average rating of “Moderate Buy” and an average target price of $110.91.

About Structure Therapeutics

Structure Therapeutics is a clinical-stage biopharmaceutical company developing medicines for metabolic and other chronic diseases. Its research approach uses structural biology and computational methods to identify and design small-molecule drug candidates.

The company’s pipeline includes aleniglipron, an oral small-molecule GLP-1 receptor agonist being developed for obesity and related metabolic conditions. Structure Therapeutics is also advancing other drug candidates targeting biological pathways associated with metabolic disease.

Founded in 2016, the company has operations in the United States and China.